Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 22;13(1):5.
doi: 10.1186/s12348-022-00321-2.

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

Affiliations

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

A Martens et al. J Ophthalmic Inflamm Infect. .

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) have become an important part of the treatment of multiple cancers, especially for advanced melanoma and non-small cell lung cancer. Some tumors are capable of escaping immunosurveillance by stimulating checkpoints on T-cells. ICIs prevent activation of these checkpoints and thereby stimulate the immune system and indirectly the anti-tumor response. However, the use of ICIs is associated with various adverse events. Ocular side effects are rare but may have a major impact on the quality of life of the patient.

Methods: A comprehensive literature search of the medical databases Web of Science, Embase and PubMed was performed. Articles that provided a comprehensive description of a case report containing 1) cancer patient(s) treated with (a combination of) immune checkpoint inhibitors, and 2) assessed occurrence of ocular adverse events, were included. A total of 290 case reports were included.

Results: Melanoma (n = 179; 61.7%) and lung cancer (n = 56; 19.3%) were the most frequent reported malignancies. The primary used ICIs were nivolumab (n = 123; 42.5%) and ipilimumab (n = 116; 40.0%). Uveitis was most the common adverse event (n = 134; 46.2%) and mainly related to melanoma. Neuro-ophthalmic disorders, including myasthenia gravis and cranial nerve disorders, were the second most common adverse events (n = 71; 24.5%), mainly related to lung cancer. Adverse events affecting the orbit and the cornea were reported in 33 (11.4%) and 30 cases (10.3%) respectively. Adverse events concerning the retina were reported in 26 cases (9.0%).

Conclusion: The aim of this paper is to provide an overview of all reported ocular adverse events related to the use of ICIs. The insights retrieved from this review might contribute to a better understanding of the underlying mechanisms of these ocular adverse events. Particularly, the difference between actual immune-related adverse events and paraneoplastic syndromes might be relevant. These findings might be of great value in establishing guidelines on how to manage ocular adverse events related to ICIs.

Keywords: Eye; Immune checkpoint inhibitors; Immune related adverse event; Paraneoplastic.

PubMed Disclaimer

Conflict of interest statement

No conflicting relationship exists for any author.

Figures

Fig. 1
Fig. 1
Mechanism of action. A Tumor antigen presentation by the major histocompatibility complex (MHC) receptor and B7/CD28 costimulatory signal are both necessary for CD8 T-cell activation. CTLA-4 downregulates T-cell immune function. Anti-CTLA-4 antibodies inhibit this downregulation and stimulate the immune system. B Interaction between PD1 and PD-L1 takes place in the lymph node and in the tumor microenvironment. PD1 downregulates T-cell function as well. Trough PD-L1 binding PD1, tumors can escape immunosurveillance. Anti-PD-1 or -PD-L1 antibodies prohibit this and will restore the anti-tumor response
Fig. 2
Fig. 2
Flowchart of the systematic search and selection process following the Prisma statement
Fig. 3
Fig. 3
Use of ICIs related to the primary tumor
Fig. 4
Fig. 4
Reported ocular side effects
Fig. 5
Fig. 5
Reported ocular side effects according to the primary tumor / ICI used

References

    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466. - DOI - PMC - PubMed
    1. Cousin S, Seneschal J, Italiano A. Toxicity profiles of immunotherapy. Pharmacol Ther. 2018;181:91–100. doi: 10.1016/j.pharmthera.2017.07.005. - DOI - PubMed
    1. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–1078. doi: 10.1097/IAE.0000000000002181. - DOI - PubMed
    1. Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford) 2019;58(Suppl 7):vii7–vii16. doi: 10.1093/rheumatology/kez418. - DOI - PMC - PubMed
    1. Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294. doi: 10.1097/CCO.0000000000000296. - DOI - PubMed

Publication types

LinkOut - more resources